ST elevation myocardial infarction (STEMI)
Conditions
Brief summary
Composite of major adverse cardiac and cerebral events (MACCE), consisting of: Myocardial infarction; Stent thrombosis; Ischemic stroke;Cardiovascular mortality., Infarct size and size of IMH determined by CMR at day 5-8 post-PPCI.
Detailed description
Bleeding complications BARC ≥ 2, All-cause mortality, To compare platelet reactivity between ticagrelor monotherapy and ticagrelor + ASA., To assess the anti-inflammatory effects of ticagrelor with or without aspirin on the inflammation response elicited by the myocardial infarction., To assess coagulation factors after the myocardial infarction in patients using ticagrelor with or without aspirin.
Interventions
Sponsors
Radboud universitair medisch centrum Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of major adverse cardiac and cerebral events (MACCE), consisting of: Myocardial infarction; Stent thrombosis; Ischemic stroke;Cardiovascular mortality., Infarct size and size of IMH determined by CMR at day 5-8 post-PPCI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding complications BARC ≥ 2, All-cause mortality, To compare platelet reactivity between ticagrelor monotherapy and ticagrelor + ASA., To assess the anti-inflammatory effects of ticagrelor with or without aspirin on the inflammation response elicited by the myocardial infarction., To assess coagulation factors after the myocardial infarction in patients using ticagrelor with or without aspirin. | — |
Countries
Netherlands
Outcome results
None listed